Noncovalent interactions allow our world to exist [...].
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7794748 | PMC |
http://dx.doi.org/10.3390/molecules26010158 | DOI Listing |
Circulation
January 2025
Department of Internal Medicine, Division of Cardiovascular Medicine, Pauley Heart Center, Virginia Commonwealth University, Richmond.
JAMA Intern Med
January 2025
Associate Editor, JAMA Internal Medicine.
Rheumatol Ther
January 2025
Saitama Medical University, 38 Morohongo, Moroyama-machi, Iruma-gun, Saitama, 350-0495, Japan.
Introduction: Ozoralizumab (OZR) is a novel tumor necrosis factor (TNF) inhibitor that was launched in Japan for treating patients with rheumatoid arthritis (RA) who have had an inadequate response to existing therapies. This post-hoc analysis aimed to compare the efficacy of OZR administered without methotrexate (MTX) with placebo or OZR administration in combination with MTX.
Methods: We analyzed the OZR group (30 mg) in the NATSUZORA trial (non-MTX, open trial) (OZR group; n = 94) and the placebo group (MTX group; n = 75) and the 30-mg OZR group (OZR + MTX group; n = 152) in the OHZORA trial (combined MTX, double-blind trial), and the covariates were adjusted by propensity score matching.
Intensive Care Med
January 2025
Department of Emergency Medicine, SUNY Downstate Health Sciences University, Brooklyn, NY, USA.
Allergy
January 2025
Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University of Madrid, Madrid, Spain.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!